Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. - Wikidata - wikimedia - TriplyDB

Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

http://www.wikidata.org/entity/Q53354602

about

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG).Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.Allogeneic hematopoietic cell transplantation in septuagenarians A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis.Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and mu Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients Blood Research: a new journey of passion with harmony beyond Asia onto the world Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation.Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Reduced-intensity conditioned allogeneic SCT in adults with AML.Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT.Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of E Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation.Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients

P2860

Q33917170-BFE19745-939D-4701-8F67-59511653E031 Q34402494-1D15E8C0-0853-491A-9B5D-A82AD55DC822 Q34544439-189473A5-97B2-4C54-B22C-14CCEC82C0C4 Q34807259-50A697A1-37EF-427B-BD78-BA4BE7CA94D5 Q35647641-579E127F-7526-4617-85CA-CFBE30EB0729 Q35766718-CEFB1502-3A33-4B68-BC0C-543BD0CD4A1C Q36157163-FB589BA0-2D99-4B26-86E4-3E4B25012D4B Q36157233-56777821-AB8C-48FB-BCAA-CC82FB0F1956 Q36182610-0C359386-9B16-4A09-96C0-46288F4096B2 Q36608468-C414C986-B3DB-4153-8B9B-54B3079281C8 Q36703516-5BA8440F-0E2C-4F8C-9637-7CD4EED3C46F Q36715911-45A0907C-D4D6-43D0-AD13-3D271C556505 Q36742108-29457ACF-9427-4BE3-B8C4-854C8CFBD9FE Q36761819-AB074050-E8B6-40C5-AC03-39718D35BE50 Q36792818-BB3705A7-BF52-4E29-B3B1-BBACF9A36C49 Q37370651-67D36F5E-F27F-4F05-903B-E4C49A80984B Q37397003-8DB3F722-F8CB-4780-8DFF-B5E12CC9C536 Q37718826-7DCC0199-0B19-41A1-9101-26B41DA1E5F9 Q38199056-115EB8CF-9E4F-4FC5-AF0E-83119A0DECAF Q38366632-2419687B-DE77-4D29-A8DB-B9620BFC5244 Q38604900-46E481E6-2664-4F82-8350-C3C2A2668D0C Q38777460-638D242B-B060-4055-88FB-222F07D1A698 Q39306717-A3557B67-6096-43E4-856B-764346639AD1 Q39632454-94FD7311-8813-4C2C-8AC1-81A75FDED009 Q40129891-7A73BE1D-A7A4-42AF-8913-EE6BE1EA65B2 Q41200444-8B4CCBFA-DAB5-4971-9DBE-28D1BDE52B34 Q42175192-9FD9D481-8CFF-40EA-BDC7-8B0DE982568A Q45235834-CB69D1B5-0ACF-400D-B376-4FF585621C5C Q46788345-E2BE5562-25D1-4AE3-A872-565438567DBC Q47144269-8B3B55E5-A6FF-483D-AE11-5B29D2ED097E Q47211374-D5460A44-B6D9-47D6-94B5-4D118B4C41AA Q48551157-C8AC406A-3DD8-4C14-A093-5708AD02FC06 Q49790702-2C8593D7-BC92-4612-B930-EC8A41355932 Q53346369-DDFFB55F-9FF5-49C9-9C81-FE90A6252261 Q54179395-C5C6461D-04CE-4521-A0B7-975FEA1ABDDA Q58798385-6FFA4CE2-8677-446D-9C2E-593DF4EB2A83

P2860

Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

http://www.wikidata.org/entity/Q53354602

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Randomized trial of myeloablat ...... sus busulfan plus fludarabine.

@en

Randomized trial of myeloablat ...... sus busulfan plus fludarabine.

@nl

type

label

Randomized trial of myeloablat ...... sus busulfan plus fludarabine.

@en

Randomized trial of myeloablat ...... sus busulfan plus fludarabine.

@nl

prefLabel

Randomized trial of myeloablat ...... sus busulfan plus fludarabine.

@en

Randomized trial of myeloablat ...... sus busulfan plus fludarabine.

@nl

P1433

Q53354602-4F8F9C09-F1E0-46B7-83B5-9EC4E02CC834

P1476

Q53354602-F3450028-BAAD-4758-8325-FBAEE9F3C38B

P2093

Q53354602-02785D8B-2961-4ADE-A045-6B5B84D21234

Q53354602-200E8D21-271E-484C-A1A1-6A3858FEBD18

Q53354602-5AC1A16E-C8B8-49A1-8E1D-9C54F2A7C67C

Q53354602-6B5D4C68-20BB-4449-A183-9BE4E541439A

Q53354602-7F5A0CFF-33A3-4DE9-BB4B-2A145850894D

Q53354602-80850051-F3AA-42BB-A5BC-9BCF9020DDDA

Q53354602-8DAE5EF7-FE1F-4043-9748-C661CEE971AF

Q53354602-9C2AAFA0-AA1B-48B1-A5D6-11DF3344658D

Q53354602-A1497A45-593F-4CF3-A877-77869ABA0B21

Q53354602-BAC8A7B3-D769-431B-8435-C592AF487C10

P304

Q53354602-F9297510-5753-4FDF-9FD0-FC7275A6E370

P31

Q53354602-D6644F1A-8A36-405F-B0FD-64C842C0AB78

P356

Q53354602-89DC8EAE-09EE-4FB7-B99A-B253AD90460A

P407

Q53354602-2AD16AC5-6D6F-44D3-83E3-EA4630813620

P433

Q53354602-64EC1945-612E-4161-80F2-D6CC0B7835F5

P478

Q53354602-C8931C4E-B746-4066-9FE2-B6182660E050

P577

Q53354602-C171A007-F590-4958-AD11-6DDC0341D155

P5875

Q53354602-28194C67-8187-48F0-9A7E-BCE21D723572

P698

Q53354602-AAA77149-227E-418A-B12C-4D03A49BBBBF

P356

JCO.2011.40.2362

P1433

Journal of Clinical Oncology

P1476

Randomized trial of myeloablat ...... sus busulfan plus fludarabine.

@en

P2093

Dae-Young Kim

http://www.w3.org/2001/XMLSchema#string

Gyeong-Won Lee

http://www.w3.org/2001/XMLSchema#string

Hawk Kim

http://www.w3.org/2001/XMLSchema#string

Hun Mo Ryoo

http://www.w3.org/2001/XMLSchema#string

Jae-Hoo Park

http://www.w3.org/2001/XMLSchema#string

Je-Hwan Lee

http://www.w3.org/2001/XMLSchema#string

Jung-Hee Lee

http://www.w3.org/2001/XMLSchema#string

Kyoo-Hyung Lee

http://www.w3.org/2001/XMLSchema#string

Min Kyoung Kim

http://www.w3.org/2001/XMLSchema#string

Myung Soo Hyun

http://www.w3.org/2001/XMLSchema#string

P304

701-709

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.40.2362

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232920986

http://www.w3.org/2001/XMLSchema#string

P698

23129746

http://www.w3.org/2001/XMLSchema#string